Simvastatin as a Neuroprotective Treatment for Moderate Parkinson's Disease

University Hospital Plymouth NHS Trust235 enrolled

Overview

Participants are randomly allocated to one of two treatment groups. In one group, participants are given capsules of simvastatin to take orally (by mouth) for 24 months. In the other group, participants are given placebo (dummy) capsules to take orally for 24 months. At the start of the study, when they receive their medication, participants complete a number of questionnaires and motor (movement) tests (a walking test and a finger tapping test). Participants in both groups also attend a further 6 clinic visits after 1, 6, 12, 18 and 24 and 26 months, where they are asked about their health and any medication they are taking, as well as repeating the questionnaires and motor tests. For 4 of the clinic visits, the participants will be asked to attend in the 'OFF medication' state (having omitted their usual PD medication) so that the researchers can get a true picture of their disease without it being masked by their normal medication.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

235

Conditions

Parkinson Disease

Interventions

Eligibility

Sex: ALLMin age: 40 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of idiopathic PD * Modified Hoehn and Yahr stage ≤ 3.0 in the ON medication state * Age 40-90 years * On dopaminergic treatment with wearing-off phenomenon * Able to comply with study protocol and willing to attend necessary study visits Exclusion Criteria: * Diagnosis or suspicion of other cause for parkinsonism * Known abnormality on CT or MRI brain imaging considered to be causing symptoms or signs of neurological dysfunction, or considered likely to compromise compliance with study protocol * Concurrent dementia defined by MoCA score \<21 * Concurrent severe depression defined by MADRS score \>31 * Prior intracerebral surgical intervention for PD including deep brain stimulation, lesional surgery, growth factor administration, gene therapy or cell transplantation * Already actively participating in a research study that might conflict with this trial * Prior or current use of statins as a lipid lowering therapy * Intolerance to statins * Untreated hypothyroidism * End stage renal disease (creatinine clearance \<30 mL/min) or history of severe cardiac disease (angina, myocardial infarction or cardiac surgery in preceding two years) * eGFR \<30 mL/min * History of alcoholism or liver impairment * Creatine kinase (CK) \>1.1 x upper limit of normal (ULN) * Aspartate transaminase (AST) or alanine transaminase (ALT) \>1.1 x ULN * Females who are pregnant or breast feeding or of child-bearing potential and unwilling to use appropriate contraception methods whilst on trial treatment * Currently taking any medication contraindicated with simvastatin use (Appendix 2) * Any requirement for statin use * Regular participation in endurance or high-impact sports * Unable to abstain from consumption of grapefruit-based products

Locations (24)

Royal United Hospital

Bath, United Kingdom

Royal Bournemouth Hospital

Bournemouth, United Kingdom

Fairfield General Hospital

Bury, United Kingdom

Addenbrooke's Hospital

Cambridge, United Kingdom

St Peter's Hospital

Chertsey, United Kingdom

Royal Devon and Exeter Hospital

Exeter, United Kingdom

Leeds General Infirmary

Leeds, United Kingdom

Charing Cross Hospital

London, United Kingdom

King's College Hospital

London, United Kingdom

Royal Free Hospital

London, United Kingdom

...and 14 more locations

Outcomes

Primary Outcomes

Change in MDS-UPDRS part III (OFF) score

The MDS-UPDRS is the standard validated tool for the assessment of patients with Parkinson's Disease. This scale includes subsections collecting data regarding the impact of PD on a patient's mood and mental state, (UPDRS part I), their activities of daily living (UPDRS part II) an examination of the motor features of PD (UPDRS part III), and complications arising from the use of dopamine replacement (part IV).

Time frame: Baseline and 24 Months